The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid β-Amyloid 42 in Adults With Normal Cognition
Abstract
BACKGROUND: Decreased cerebrospinal fluid (CSF) beta-amyloid 42 (A beta 42) concentration, but not A beta 40 concentration, is a biomarker for Alzheimer disease. This A beta 42 concentration decrease in CSF likely reflects precipitation of A beta 42 in amyloid plaques in brain parenchyma. This pathogenic plaque deposition begins years before the clinical expression of dementia in Alzheimer disease. Normal aging and the presence of the apolipoprotein E (APOE*4) allele are the most important known risk factors for Alzheimer disease. OBJECTIVE: To estimate the interactive effects of normal aging and presence of the APOE*4 allele on CSF A beta 42 concentration in adults with normal cognition across the life span. DESIGN: The CSF was collected in the morning after an overnight fast using Sprotte 24-g atraumatic spinal needles. The CSF A beta 42 and A beta 40 concentrations were measured in the 10th milliliter of CSF collected by sandwich enzyme-linked immunosorbent assay. The APOE genotype was determined by a restriction digest method. Subjects One hundred eighty-four community volunteers with normal cognition aged 21 to 88 years. RESULTS: The CSF A beta 42, but not the A beta 40, concentration decreased significantly with age. There was a sharp decrease in CSF A beta 42 concentration beginning in the sixth decade in subjects with the APOE*4 allele. This age-associated decrease in CSF A beta 42 concentration was significantly and substantially greater in subjects with the APOE*4 allele compared with those without the APOE*4 allele. CONCLUSION: These CSF A beta 42 findings are consistent with acceleration by the APOE*4 allele of pathogenic A beta 42 brain deposition starting in later middle age in persons with normal cognition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies of non-demented individuals report that while CSF Aβ levels seem to decline during young adulthood, during late mid-life CSF Aβ levels may actually slightly increase [219, 220].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [220]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053
Mild cognitive impairment in the elderly: Predictors of dementia
Flicker, C., Ferris, S. H., & Reisberg, B. (1991) · Neurology · doi:10.1212/wnl.41.7.1006 · Cited by 838
Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain
Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos, L., Younkin, L. H., Suzuki, N., & Younkin, S. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7013 · Cited by 676 · cited 7×
“The A peptide is generated by proteolytic processing of the amyloid precursor protein into a series of fragments 38 to 42 amino acids long; A 42 represents about 10% of synthesized A but is by far the earliest and predominant A species deposited in plaques in AD.(5) Decreased concentration of A 42 in CSF is a consiste…”
BackgroundInfluentialCSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 621
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–131 of 131
Ye, C., Albert, M., Brown, T., Bilgel, M., Hsu, J., Ma, T., Caffo, B. C., Miller, M. I., Mori, S., & Oishi, K. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02074 · Cited by 5
Time Will Be of the Essence in Treating Alzheimer Disease
Rosenberg, R. N. (2006) · JAMA · doi:10.1001/jama.296.3.327 · Cited by 4
Tissue Factor and Its Cerebrospinal Fluid Protein Profiles in Parkinson’s Disease
Zimmermann, M., Fandrich, M., Jakobi, M., Röeben, B., Wurster, I., Lerche, S., Schulte, C., Zimmermann, S., Deuschle, C., Schneiderhan‐Marra, N., et al. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240115 · Cited by 3
Liang, K. J., Colasurdo, E. A., Li, G., Shofer, J. B., Galasko, D. R., Quinn, J. F., Farlow, M. R., & Peskind, E. R. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae220 · Cited by 3
Self-citationBiomarkers of Disorders of the Nervous System
Jain, K. K. (2017) · Springer eBooks · doi:10.1007/978-1-4939-7431-3_14 · Cited by 3
Jansson, D., Shofer, J. B., Colasurdo, E. A., Schindler, A. G., Li, G., Adler, C. H., Balcer, L. J., Bernick, C. B., Daneshvar, D. H., Katz, D. I., et al. (2026) · Journal of Neurotrauma · doi:10.1177/08977151251390520 · Cited by 2
Self-citationApo E gene polymorphism in patients with metabolic syndrome and cognitive disorders
Зуева, И. Б., Ulitina, A., Ghorab, D. N., Москаленко, М. В., & Dubina, M. (2012) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2012-18-5-421-428 · Cited by 2
Cerebrospinal fluid soluble insulin receptor levels in Alzheimer's disease
Thomas, P., Leclerc, M., Evitts, K. M., Brown, C., Miller, W., Hanson, A. J., Banks, W. A., Gibbons, L. E., Domoto‐Reilly, K., Jayadev, S., et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12603 · Cited by 2
Self-citationAlzheimer's Disease: Approaches to Pathogenesis in the Genomic Age
Sutherland, G. T., & Jillian, J. (2012) · InTech eBooks · doi:10.5772/36505 · Cited by 2
A shift in the paradigm of treatment.
Howe, E. G. (2006) · PubMed Central · Cited by 2
The effect of chronic hyperglycemia on aging: implications in cognitive impairment
Sarkar, A., Saha, S., & Bhattacharya, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00027-x · Cited by 1
Biomarkers of Neurological Disorders
Jain, K. K. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-272-8_4 · Cited by 1
CSF biomarkers in dementia: longitudinal aspects and combination with MRI
Bouwman, F. H. (2008) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · Cited by 1
Rosenberg, R. N. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.926 · Cited by 1
11 The Early Detection of Alzheimer's Disease with Positron Emission Tomography
Mistur, R. L., Mosconi, L., Switalski, R., Santi, S. D., Li, Y., Glodzik, L., Bryś, M., Tsui, W., Rusinek, H., & de Leon, M. J. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195328875.003.0011 · Cited by 1
Biomarkers of Disorders of the Nervous System
Jain, K. K. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-685-6_7 · Cited by 1
Cerebrospinal Fluid: When Is It Worthwhile to Do a Lumbar Puncture?
Peskind, E. R. (2008) · CNS Spectrums · doi:10.1017/s1092852900027012
Self-citationSPECIFIC AMYLOID-BETA OLIGOMERS IN HUMAN CEREBROSPINAL FLUID
Handoko, M. (2012) · University of Minnesota Digital Conservancy (University of Minnesota)
Xiong, C., van Belle, G., Zhu, K., Miller, J. P., & Morris, J. C. (2010) · Journal of Applied Statistics · doi:10.1080/02664760903008987
Yaiw, K.-C., Eu, L. C., Fang, C.-M., Ong, B. B., Qvist, R., & Wong, K. T. (2012)
Cerebral white matter changes : Differentiating vascular and degenerative cognitive impairment
Stenset, V. T. V. (2009) · NORA - Norwegian Open Research Archives
Яхьяевич, Я. Н., & Vagabov, N. M. (2009) · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES
Saint‐Aubert, L. (2012) · Thèses en ligne de l'Université Toulouse III (Université Toulouse III)
Stadnik, S. M. (2022) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.18.2.2022.936
Characteristics of Alzheimer’s Disease and Mild Cognitive Impairment Influenced by the Time of Onset
Sato, H., Ota, M., Kitabatake, A., Numata, Y., Takahashi, T., Tamura, M., Nemoto, K., & Arai, T. (2024) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000541092
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047440
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047446
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047443
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047449
Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13047452
Hey, J. A., Geerts, H., Schaefer, J. F., Short, S. M., van der Graaf, P. H., Abushakra, S. R., Power, A., Tolar, M., & Yu, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-10570608/v1
Metadata
- Authors
- Peskind, E. R., Li, G., Shofer, J., Quinn, J. F., Kaye, J. A., Clark, C. M., Farlow, M. R., DeCarli, C., Raskind, M. A., Schellenberg, G. D., Lee, V. M.-Y., & Galasko, D. R.
- Affiliations
- University of Washington (US)
- Oregon Health & Science University (US)
- University of Pennsylvania (US)
- Indiana University – Purdue University Indianapolis (US)
- University of California, Davis (US)
- University of California San Diego (US)
- ORCID
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2006-07-01
- Volume
- 63
- Issue
- 7
- Pages
- 936
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2104954974
- Cited by
- 131
- References
- 20
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 7 · 2019: 4 · 2018: 2 · 2017: 7 · 2016: 3 · 2015: 5 · 2014: 4 · 2013: 14 · 2012: 17
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag008419-15)
- National Institute on Aging (AG 10133, P30AG010133, AG08419, AG 08017, AG23185, AG 05136, P30AG010124, P30AG008017, AG-10124, R01AG023185, P50AG005136)
- National Center for Research Resources (M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Aβ40, normal aging, Alzheimer's disease risk, cerebrospinal fluid biomarkers, normal cognition
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aging, Alleles, Apolipoproteins E, Brain, Cognition, Female, Genotype, Humans, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
